Enteric-Coated, Uncoated Aspirin Have Similar Effectiveness in Heart Patients
Findings seen for secondary prevention among patients with cardiovascular disease
Source: renalandurologynews.com
Stay updated with breaking news from Amber Sleem. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings seen for secondary prevention among patients with cardiovascular disease
There is no significant difference in the primary effectiveness or safety between enteric-coated aspirin and uncoated aspirin among patients with cardiovascular disease.
The coating didn’t appear to diminish GI bleeding but, in better news, also didn’t dampen aspirin’s antiplatelet effects.
There is no decrease in efficacy but no significant benefit of enteric-coated aspirin over uncoated aspirin in patients with cardiovascular disease, post hoc results of the ADAPTABLE trial suggest.